New treatment approach for heart failure using small molecules
Official title: Small Molecule Therapeutic for Heart Failure
Funded at Cleveland Clinic Lerner Com-Cwru · NIH-11001484 · Data updated 2026-11-12
This study is looking at a new medication that could help people with heart failure by making their hearts work better when responding to important hormones, and it uses special tests and mouse models to see how well it works.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Cleveland Clinic Lerner Com-Cwru NIH-funded |
| Lab location | 1 site (Cleveland, United States) |
| Project start | December 15, 2023 |
| Project end | November 30, 2025 |
| Funding year | 2025 |
| Award (this year) | $499,322 |
| NIH project number | 5R61HL171717-02 |
| Project ID | NIH-11001484 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are adults aged 21 and older who are diagnosed with heart failure.
✕Less likely to help
Patients with heart failure who are under 21 years old or those with other severe comorbidities may not benefit from this research.
What this research studies
This research investigates a novel small molecule therapeutic aimed at improving heart function in patients with heart failure. It focuses on the mechanisms of beta-adrenergic receptor (βAR) desensitization and resensitization, which are crucial for cardiac function. By targeting specific proteins that regulate these processes, the research aims to enhance the heart's ability to respond to hormones like epinephrine and norepinephrine, potentially leading to better heart performance. The study will utilize advanced biochemical assays and mouse models to evaluate the effectiveness of the treatment.
Why it matters
Potential benefit: If successful, this research could lead to improved heart function and quality of life for patients suffering from heart failure.
How similar studies have gone: Previous research has shown promising results in targeting βAR resensitization, indicating potential for success in this novel approach.
Where this research is happening
-
Cleveland Clinic Lerner Com-Cwru
Cleveland, United States Active
Researchers
- Principal investigator: Prasad, Sathyamangla V — Cleveland Clinic Lerner Com-Cwru
- Study coordinator: Prasad, Sathyamangla V
Related research
Other NIH-funded projects on the same topics.
-
AI-supported heart failure diagnosis and management in Rwanda
Aiming to help people with suspected heart failure in Rwanda get faster, more accurate diagnoses and better care using AI-guided ultrasound and care protocols.
-
AI-assisted heart failure diagnosis in Rwanda using focused ultrasound
An NIH-funded project will test whether AI-enhanced, easy-to-use heart ultrasound can help non-experts diagnose and manage heart failure in Rwanda.
-
HF endotypes in heart failure using ethical multi-modal AI and molecular data
A patient-friendly project that uses advanced AI and multiple kinds of health data to identify distinct heart failure subtypes that could guide personalized care.
-
Triple gene therapy approach to heal the heart after a heart attack
A new therapy combines three genetic approaches delivered by a virus to help the heart heal after a heart attack.
-
Digital-first heart failure care delivery in Uganda
A targeted program in Uganda tests a digital care plan to help people with heart failure manage their symptoms at home.
-
Digital-first heart failure care delivery in Uganda
A study to test digital self-care tools to help people with heart failure in Uganda manage symptoms and stay healthier.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.